BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

Terms: = Ovarian cancer AND PIK3CA, MGC142161, 5290, ENSG00000121879, P42336, MGC142163, p110-alpha, PI3K AND Staging
11 results:

  • 1. Pan-cancer Analysis Reveals cancer-dependent Expression of SOX17 and Associated Clinical Outcomes.
    Xu LI; Bai Y; Cheng Y; Sheng X; Sun D
    Cancer Genomics Proteomics; 2023; 20(5):433-447. PubMed ID: 37643784
    [TBL] [Abstract] [Full Text] [Related]  

  • 2. Extrauterine Mesonephric-like Carcinoma: A Comprehensive Single Institution Study of 33 Cases.
    Euscher ED; Marques-Piubelli ML; Ramalingam P; Wistuba I; Lawson BC; Frumovitz M; Malpica A
    Am J Surg Pathol; 2023 Jun; 47(6):635-648. PubMed ID: 37026792
    [TBL] [Abstract] [Full Text] [Related]  

  • 3. Clear cell carcinoma of the ovary: Epidemiology, pathological and biological features, treatment options and clinical outcomes.
    Gadducci A; Multinu F; Cosio S; Carinelli S; Ghioni M; Aletti GD
    Gynecol Oncol; 2021 Sep; 162(3):741-750. PubMed ID: 34247767
    [TBL] [Abstract] [Full Text] [Related]  

  • 4. Determination of Potential Therapeutic Targets and Prognostic Markers of ovarian cancer by Bioinformatics Analysis.
    Zhang J; Huang S; Quan L; Meng Q; Wang H; Wang J; Chen J
    Biomed Res Int; 2021; 2021():8883800. PubMed ID: 33829065
    [TBL] [Abstract] [Full Text] [Related]  

  • 5. Inhibition of Ca
    Liu Z; Zhang S; Hou F; Zhang C; Gao J; Wang K
    Int J Cancer; 2019 May; 144(9):2215-2226. PubMed ID: 30243029
    [TBL] [Abstract] [Full Text] [Related]  

  • 6. Mutational status of KRAS, NRAS, and BRAF in primary clear cell ovarian carcinoma.
    Zannoni GF; Improta G; Chiarello G; Pettinato A; Petrillo M; Scollo P; Scambia G; Fraggetta F
    Virchows Arch; 2014 Aug; 465(2):193-8. PubMed ID: 24889043
    [TBL] [Abstract] [Full Text] [Related]  

  • 7. The involvement of RhoA and Wnt-5a in the tumorigenesis and progression of ovarian epithelial carcinoma.
    Chen S; Wang J; Gou WF; Xiu YL; Zheng HC; Zong ZH; Takano Y; Zhao Y
    Int J Mol Sci; 2013 Dec; 14(12):24187-99. PubMed ID: 24351810
    [TBL] [Abstract] [Full Text] [Related]  

  • 8. Loss of ARID1A expression and its relationship with pi3k-Akt pathway alterations and ZNF217 amplification in ovarian clear cell carcinoma.
    Huang HN; Lin MC; Huang WC; Chiang YC; Kuo KT
    Mod Pathol; 2014 Jul; 27(7):983-90. PubMed ID: 24336158
    [TBL] [Abstract] [Full Text] [Related]  

  • 9. Lewis Y regulates signaling molecules of the transforming growth factor β pathway in ovarian carcinoma-derived RMG-I cells.
    Li FF; Liu JJ; Liu DW; Lin B; Hao YY; Cong JP; Zhu LC; Gao S; Zhang SL; Iwamori M
    Int J Oncol; 2012 Apr; 40(4):1196-202. PubMed ID: 22179544
    [TBL] [Abstract] [Full Text] [Related]  

  • 10. Lewis y antigen promotes the proliferation of ovarian carcinoma-derived RMG-I cells through the pi3k/Akt signaling pathway.
    Liu J; Lin B; Hao Y; Qi Y; Zhu L; Li F; Liu D; Cong J; Zhang S; Iwamori M
    J Exp Clin Cancer Res; 2009 Dec; 28(1):154. PubMed ID: 20003467
    [TBL] [Abstract] [Full Text] [Related]  

  • 11. [Expression of phosphatidylinositol-3 kinase in epithelial ovarian carcinoma].
    Zhang PN; Sun H
    Zhonghua Fu Chan Ke Za Zhi; 2007 Mar; 42(3):196-200. PubMed ID: 17537308
    [TBL] [Abstract] [Full Text] [Related]  


    of 1.